share_log

诺诚健华(688428.SH)：坦昔妥单抗联合治疗复发或难治性弥漫性大B细胞淋巴瘤的BLA获受理

Innocare (688428.SH): The BLA for combination therapy of Tanxetru with single-agent for relapsed or refractory diffuse large B-cell lymphoma has been accepted.

Zhitong Finance ·  Jun 20 19:57

Innocare (688428.SH) announced that the company's innovative drug tafasitamab (Tenximidone) monoantibody for biological product license (BLA) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who are not suitable for autologous stem cell transplantation (ASCT), has recently been accepted by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for priority review.

Zhifubao Finance and Economics APP, innocare (688428.SH) announced that the company's innovative drug tafasitamab (Tenximidone) monoantibody has been accepted by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for priority review, for biological product license (BLA) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who are not suitable for autologous stem cell transplantation (ASCT).

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment